Compare GlobalFoundries Inc. Ordinary Shares (GFS) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GlobalFoundries Inc. Ordinary Shares vs Hinge Health Inc. Class A Common Stock — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $47.41 (market cap $26.95B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: GlobalFoundries Inc. Ordinary Shares is far larger — about 3.2× Hinge Health Inc. Class A Common Stock's market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.99% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 1 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GFS | HNGE | |
|---|---|---|
Market Cap | $26.95B | $8.48B |
Volume | 7,717,478 | 879,799 |
Sector | Technology | Health |
52-Week High | $89.96 | $105.14 |
52-Week Low | $32.24 | $31.17 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $26.24B | $8.10B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GlobalFoundries (GFS) trades at $46.70, down 3.39% on the day, with technical indicators showing a neutral to bearish short-term bias. The company maintains solid fundamentals with $6.79B revenue and 10.32% net margin, though profitability declined year-over-year. Recent catalysts include a landmark $21B Japan-backed fab expansion and strategic partnerships with TSMC and Marvell for AI-related semiconductor production, positioning GFS for long-term growth in the semiconductor sector.
While near-term technical weakness persists, GFS's strategic positioning in AI infrastructure and substantial government-backed expansion create compelling long-term opportunities. Risks include execution challenges with massive capital projects and semiconductor cycle volatility. With 57.9% analyst buy ratings and a $79.69 consensus target representing 71% upside, Wall Street remains optimistic about GFS's growth trajectory despite current market softness.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GlobalFoundries Inc. Ordinary Shares
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
